Critical Review: NRx Pharmaceuticals and Ionis Pharmaceuticals

Comparing the medical companies' performance and investment potential

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

This article provides a critical review and comparison of two medical companies, NRx Pharmaceuticals (NASDAQ:NRXP) and Ionis Pharmaceuticals (NASDAQ:IONS), to determine which is the superior investment. The analysis looks at factors such as analyst recommendations, institutional ownership, profitability, valuation, and other key metrics to assess the relative strengths of the two firms.

Why it matters

Investors interested in the pharmaceutical and biotech sectors will find this analysis useful in evaluating two prominent companies in the space and making informed decisions about where to allocate their capital. The comparison highlights the differing risk profiles, growth prospects, and valuations of the two firms.

The details

The article notes that NRx Pharmaceuticals has a higher beta of 1.91, indicating its share price is 91% more volatile than the S&P 500, while Ionis Pharmaceuticals has a lower beta of 0.29, meaning its share price is 71% less volatile. In terms of profitability, the data shows Ionis Pharmaceuticals has stronger net margins, return on equity, and return on assets compared to NRx Pharmaceuticals. However, analysts believe NRx Pharmaceuticals has greater potential upside, with a consensus price target indicating 1,970% potential upside versus 5.75% for Ionis Pharmaceuticals. Institutional ownership is also much higher for Ionis Pharmaceuticals at 93.9% versus 4.3% for NRx Pharmaceuticals.

  • The article was published on February 19, 2026.

The players

NRx Pharmaceuticals

A clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.

Ionis Pharmaceuticals

A company that discovers and develops RNA-targeted therapeutics, offering treatments for spinal muscular atrophy, polyneuropathy caused by hereditary transthyretin amyloidosis, and familial chylomicronemia syndrome, among other indications.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the differing investment profiles of NRx Pharmaceuticals and Ionis Pharmaceuticals, with NRx offering potentially higher upside but also greater volatility, while Ionis demonstrates stronger profitability and institutional backing. Investors will need to carefully weigh the risks and rewards of each company based on their individual investment objectives and risk tolerance.